Sphera Funds Management LTD. Invests $3.66 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Sphera Funds Management LTD. bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 68,333 shares of the company's stock, valued at approximately $3,659,000. Sphera Funds Management LTD. owned 0.13% of Janux Therapeutics at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Ratan Capital Management LP lifted its holdings in Janux Therapeutics by 522.6% during the fourth quarter. Ratan Capital Management LP now owns 179,307 shares of the company's stock valued at $9,600,000 after purchasing an additional 150,507 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Janux Therapeutics by 57.0% in the fourth quarter. Point72 Asset Management L.P. now owns 621,383 shares of the company's stock worth $33,269,000 after purchasing an additional 225,508 shares during the period. ProShare Advisors LLC boosted its position in shares of Janux Therapeutics by 23.9% in the fourth quarter. ProShare Advisors LLC now owns 10,384 shares of the company's stock worth $556,000 after purchasing an additional 2,003 shares during the period. Prosight Management LP boosted its position in shares of Janux Therapeutics by 60.9% in the fourth quarter. Prosight Management LP now owns 329,768 shares of the company's stock worth $17,656,000 after purchasing an additional 124,768 shares during the period. Finally, MPM Bioimpact LLC boosted its position in shares of Janux Therapeutics by 34.4% in the fourth quarter. MPM Bioimpact LLC now owns 230,000 shares of the company's stock worth $12,314,000 after purchasing an additional 58,895 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,001 shares of company stock valued at $313,964 over the last 90 days. 8.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

JANX has been the subject of a number of recent analyst reports. Scotiabank dropped their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Trading Down 0.5%

Shares of NASDAQ:JANX traded down $0.11 during midday trading on Monday, reaching $24.17. 886,036 shares of the company were exchanged, compared to its average volume of 868,722. The business's fifty day moving average is $28.66 and its two-hundred day moving average is $40.54. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The stock has a market cap of $1.43 billion, a PE ratio of -20.66 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.